Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...
Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
In a study trial, Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in weight loss efficacy. The study was conducted by ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound ...
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...